Biocon partners with Zentiva for European marketing of Liraglutide
Biocon Limited has entered into a semi-exclusive partnership with Zentiva, a Czech pharma company for marketing its drug-device combination Liraglutide for the treatment and management of Type 2 diabetes as well as obesity.
As per the terms of the agreement, the Indian pharma company will handle Liraglutide’s manufacturing and supply to Zentiva for the commercialization of the drug device in 30 European countries.
Biocon will keep the right to market the Type 2 diabetes and obesity product under its own brand in the region.
Biocon partners with Zentiva for European marketing of Liraglutide. Photo courtesy of Biocon.
Siddharth Mittal — Biocon CEO and Managing Director said: “We are pleased to build upon our existing relationship with Zentiva for the commercialization of this complex drug product in the European markets. We look forward to leveraging our mutual strengths to achieve a common objective of creating affordable access to complex generic medicines.”
Zentiva is engaged in marketing branded generics in various therapeutic areas such as diabetes, respiratory, cardiology, and oncology. The company has four flagship pharma manufacturing plants in Bucharest, Ankleshwar, and Prague.
Abhijit Zutshi — Biocon Global Commercial Head of Generic Formulations said: “This partnership will help Biocon to achieve its strategic objective of expanding its footprint in the European market, underpinning our commitment to providing high-quality, affordable medicines to patients around the globe.”